BRD9

Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909

Retrieved on: 
Tuesday, March 5, 2024
EP300, PD, Chemistry, CBP, BRD9, Chromatin, AACR, SMARCA2, Safety, Gene expression, Thrombocytopenia, Lilly, IND, Poster, BRM, Pharmaceutical industry

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that preclinical data for its pipeline programs, including the first presentation of preclinical data for FHD-909, a potential first-in-class BRM (SMARCA2) selective inhibitor will be presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024 in San Diego, California. In addition to the FHD-909 poster, the Company will have a symposium presentation, a town hall talk, and poster presentations on its selective CBP degrader and selective EP300 degrader programs.

Key Points: 
  • In addition to the FHD-909 poster, the Company will have a symposium presentation, a town hall talk, and poster presentations on its selective CBP degrader and selective EP300 degrader programs.
  • “Our 2024 AACR presentations showcase the significant progress that Foghorn has made advancing multiple potential first-in-class medicines, based on our unique capabilities targeting the chromatin regulatory system” said Adrian Gottschalk, President and Chief Executive Officer of Foghorn.
  • In addition, we will present data highlighting our long-acting formulation capabilities that enable up to once-a-month dosing for protein degraders, which we believe meaningfully differentiate our programs and platform.”
    Symposium Session: TM04 – Losing our inhibitions – is (protein) degradation preferred?
  • : A chemistry in Cancer Research Working Group Town Hall Meeting
    Poster Title: Identification of selective CBP degraders with robust preclinical PK, PD, efficacy and safety across solid tumor indications
    Poster Title: Long acting injectable FHD-609 micro-suspension: A potent BRD9 degrader with comparable efficacy, reduced frequency of dosing in preclinical models
    The presentation and the posters will be accessible under the Science section of the Company’s website after the conference.

Rumi Scientific Announces Partnership with X-Chem for Development of Lead Candidate in Huntington’s Disease

Retrieved on: 
Tuesday, December 5, 2023
Biology, Partnership, Drug discovery, BRD9, Disease, Brain, Chem, Doctor of Philosophy, HD, Observation, Machine learning, Phenotype

RUMI Scientific has identified bromodomain 9 (BRD9), an epigenetic reader, as a novel therapeutic target for HD with the potential to modify the disease's progression.

Key Points: 
  • RUMI Scientific has identified bromodomain 9 (BRD9), an epigenetic reader, as a novel therapeutic target for HD with the potential to modify the disease's progression.
  • A key result from these studies is that lowering of BRD9 levels can restore striatal volume a significant observation demonstrating disease modifying potential.
  • "We are excited to be partnering with RUMI Scientific in their pursuit of a lead candidate iBRD9 for HD” said Matt Clark, Ph.D., Chief Executive Officer of X-Chem.
  • “RUMI Scientific's profound understanding of HD biology and their innovative drug discovery platform make them an ideal partner.

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Wednesday, November 1, 2023
Neoplasm, Controlled Impact Demonstration, Research, NSCLC, Public expenditure, National Medical Products Administration, Dexamethasone, Disease, CRC, Annual general meeting, Security (finance), Melanoma, BRAF, Wind, Caregiver, Roche, NHL, Safety, Therapy, Patient, Administration, BRAF V600, Research and development, Plasma, CCCC, Xerostomia, G&A, Conference, CTA, Synovial sarcoma, TPD, Clinical trial, ODI, Anemia, BRD9, Finance, Fatigue, Half-life, NMPA, Aes, Strategic planning, Colorectal cancer, R, High-level radioactive waste management, RECIST, Lung cancer, Combination therapy, Neutropenia, Pharmaceutical industry, Cryptocurrency, Fine chemical, Vaccine, Video game, Dysgeusia, Biogen

WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today reported financial results for the third quarter ended September 30, 2023, as well as recent business highlights.

Key Points: 
  • Revenue: Total revenue for the third quarter of 2023 was $11.1 million, compared to $6.8 million for the third quarter of 2022.
  • Research and Development (R&D) Expense: R&D expense for the third quarter of 2023 was $28.3 million, compared to $29.7 million for the third quarter of 2022.
  • Net Loss and Net Loss per Share: Net loss for the third quarter of 2023 was $27.0 million, compared to $32.0 million for the third quarter of 2022.
  • Net loss per share for the third quarter of 2023 was $0.55 compared to $0.65 for the third quarter of 2022.

C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myelom

Retrieved on: 
Wednesday, October 11, 2023
Annual general meeting, Pharmacokinetics, Research, Dexamethasone, Therapy, PK, Safety, Synovial sarcoma, Disease, CCCC, RECIST, City, BRD9, PD, Conference, Patient, Oncology, Pharmaceutical industry

WATERTOWN, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced plans to share data from the Phase 1 dose escalation portions of the ongoing Phase 1/2 trials of CFT7455 and CFT8634. The CFT8634 Phase 1 dose escalation data has been accepted as a poster presentation at the Connective Tissue Oncology Society (CTOS) Annual Meeting taking place from November 1 – 4, 2023 in Dublin, Ireland. C4T will host a company-sponsored event on December 12, 2023, to share the CFT7455 dose escalation data in relapsed/refractory multiple myeloma (R/R MM).

Key Points: 
  • C4T will host a company-sponsored event on December 12, 2023, to share the CFT7455 dose escalation data in relapsed/refractory multiple myeloma (R/R MM).
  • As of August 29, 2023, 32 patients were enrolled across six dose escalation cohorts using a daily dosing schedule.
  • Enrollment continues for the Phase 1 dose escalation evaluating CFT7455 with dexamethasone in R/R MM and as a monotherapy in R/R NHL.
  • November 14, 2023: Management will participate in the Stifel 2023 Conference taking place in New York, NY.

Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference

Retrieved on: 
Wednesday, October 4, 2023
Synovial sarcoma, AACR, UM, CBP, DLBCL, Foghorn, NGS, Chromatin, BRM, BRG1, Mum, Gene expression, NSCLC, Prostate, Biomarker, Lung cancer, EP300, Acute myeloid leukemia, B cell, MDS, Malignancy, AML, BAF, Patient, Lymphoma, Neoplasm, BRD9, AR, Conference, Prostate cancer, Pharmaceutical industry, Vaccine, Science

The conference will be held October 11–15, 2023, in Boston, Massachusetts.

Key Points: 
  • The conference will be held October 11–15, 2023, in Boston, Massachusetts.
  • Foghorn will highlight data from its FHD-286 program demonstrating its potential as a broad-based hematologic and solid tumor differentiation agent, including clinical data in acute myeloid leukemia (AML), metastatic uveal melanoma (mUM), and pre-clinical data in non-small cell lung cancer (NSCLC) and prostate cancer.
  • Also at AACR-NCI-EORTC, the Company will present data from its selective EP300 program, including in vitro selective degradation and antiproliferation in AR+ prostate and DLBCL cell lines.
  • The EP300 program targets CBP mutant cancers and subsets of EP300 dependent malignancies, which include bladder, NSCLC, and various leukemias and lymphomas.

C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, August 8, 2023
CCCC, Pharming, G&A, BRAF V600, Patient, Research and development, R, Disease, Multiple myeloma, Drug discovery, Lung cancer, Combination therapy, International Conference on Afghanistan, London (2006), Security (finance), BRD9, FDA, Conference, Safety, Appointment, Roche, BRAF, Medicine, NSCLC, Finance, Controlled Impact Demonstration, Administration, Colorectal cancer, Research, Therapy, Synovial sarcoma, Drug development, CRC, ICML, Clinical trial, Lymphoma, NHL, CNS, Dexamethasone, ASCO, Public expenditure, American Society of Clinical Oncology, Melanoma, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Food, Pharmaceutical industry, Cryptocurrency, Fine chemical, Vaccine, Video game, Biogen, Calico, IND, Mutant

WATERTOWN, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today reported financial results for the second quarter ended June 30, 2023, as well as recent business highlights.

Key Points: 
  • Revenue: Total revenue for the second quarter of 2023 was $2.7 million, compared to $13.8 million for the second quarter of 2022.
  • Research and Development (R&D) Expense: R&D expense for the second quarter of 2023 was $29.9 million, compared to $31.3 million for the second quarter of 2022.
  • General and Administrative (G&A) Expense: G&A expense for the second quarter of 2023 was $10.3 million, compared to $9.9 million for the second quarter of 2022.
  • Net loss per share for the second quarter of 2023 was $0.73 compared to $0.56 for the second quarter of 2022.

C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, May 4, 2023
Synovial sarcoma, PK, AACR, PD, CRC, CCCC, Cancer research, Biogen, Roche, Clinical trial, NHL, BRAF, G&A, NSCLC, Finance, Lung cancer, BRAF V600, Dexamethasone, Combination therapy, Public expenditure, Ongo, Investigational New Drug, Patient, Administration, Colorectal cancer, Melanoma, Annual general meeting, Research and development, BRD9, Research, R, Therapy, Security, IND, Society, Conference, Disease, Pharmaceutical industry, Cryptocurrency, Fine chemical, Medical imaging, Video game, Mutant

WATERTOWN, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today reported financial results for the first quarter ended March 31, 2023, as well as recent business highlights.

Key Points: 
  • Revenue: Total revenue for the first quarter of 2023 was $3.8 million, compared to $7.7 million for the first quarter of 2022.
  • Research and Development (R&D) Expense: R&D expense for the first quarter of 2023 was $29.0 million, compared to $26.2 million for the first quarter of 2022.
  • General and Administrative (G&A) Expense: G&A expense for the first quarter of 2023 was $10.9 million, compared to $12.8 million for the first quarter of 2022.
  • Net loss per share for the first quarter of 2023 was $0.71 compared to $0.65 for the first quarter of 2022.

Rumi Scientific Announces Data Demonstrating Disease Modifying Effect of BRD9 Inhibition in a Huntington’s Disease Animal Model

Retrieved on: 
Wednesday, April 26, 2023
HD, Neuron, CHDI, Research, Brain, Biomarker, Cerebral cortex, HIV disease progression rates, Mouse, BRD9, Therapy, IND, Conference, Disease, Pharmaceutical industry, Rumi

The research was presented at the CHDI Huntington’s Disease Therapeutics Conference, being held, April 24-27, in Dubrovnik, Croatia.

Key Points: 
  • The research was presented at the CHDI Huntington’s Disease Therapeutics Conference, being held, April 24-27, in Dubrovnik, Croatia.
  • “BRD9 inhibition is a novel target for the treatment of HD identified by our proprietary high throughput organoid phenotypic screening platform,” said Fred Etoc, Chief Scientific Officer of Rumi.
  • “We have previously demonstrated, in vitro, that BRD9 inhibition rescues several of the biochemical dysfunctions known to occur in HD and thus could be disease modifying.
  • These data demonstrate the potential of a novel disease modifying therapeutic target to reverse pathologies in a HD animal model.

Foghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry Meeting

Retrieved on: 
Thursday, April 6, 2023
Synovial sarcoma, Foghorn, Survival, Chromatin, BRD9, SPI1, Gene expression, Factorization of polynomials, Pharmaceutical industry, Science

CAMBRIDGE, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced upcoming oral presentations highlighting its transcription factor and protein degradation capabilities at the 18th Annual Drug Discovery Chemistry Meeting.

Key Points: 
  • CAMBRIDGE, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced upcoming oral presentations highlighting its transcription factor and protein degradation capabilities at the 18th Annual Drug Discovery Chemistry Meeting.
  • The hybrid meeting will be held April 10–13, 2023, at the Hilton Bayfront in San Diego, CA, and virtually.
  • The company will present preclinical data on FHD-609, a potent and selective heterobifunctional protein degrader of BRD9, a protein that synovial sarcoma cells rely on for survival.
  • Foghorn has developed a set of tools to visualize and study the interactions between transcription factors and chromatin remodeling complexes.

Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update

Retrieved on: 
Thursday, March 9, 2023
Fred Hutchinson Cancer Research Center, Survival, Mutation, Merck, Research, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Malignancy, Prostate cancer, Food, Senior, ARID1A, Drug discovery, Therapy, Breast, BAF, EP300, Selective, IND, Acute leukemia, Myelodysplastic syndrome, Chromatin, Lung cancer, BRM, CREB, Mum, Gene expression, Lymphoma, CBP, Investment, Development, ARID1B, Ionis Pharmaceuticals, Synovial sarcoma, BRG1, Cancer, NSCLC, AML, Trial of the century, MDS, Uveal melanoma, Collaboration, Patient, State Administrative Expenses, Lilly, BRD9, Lung, Leukemia, Factorization of polynomials, Safety, Pharmaceutical industry, Vaccine, Cryptocurrency, Foghorn

CAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a corporate update including the Company’s 2023 strategic priorities and 2022 key achievements in conjunction with its 10-K filing for the year ending December 31, 2022. With an initial focus in oncology, Foghorn’s Gene Traffic Control® Platform and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases.

Key Points: 
  • “2022 was a productive year for Foghorn as we made significant progress advancing our robust preclinical and clinical pipeline,” said Adrian Gottschalk, President and Chief Executive Officer of Foghorn.
  • In 2023, Foghorn will continue to leverage its Gene Traffic Control platform to discover and develop novel therapeutics based on disruptors of an undisclosed transcription factor target.
  • In 2022, Foghorn announced Steven Bellon, Ph.D., former Senior Vice President of Drug Discovery, was promoted to Chief Scientific Officer.
  • During 2022, Foghorn announced the election of B. Lynne Parshall, Esq., and Thomas J. Lynch Jr., M.D., to its Board of Directors.